ArticleCureus2025
Eosinophil Dynamics as Prognostic Indicators in Immunotherapy for Pulmonary Lymphoepithelioma-Like Carcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPulmonary lymphoepithelioma-like carcinoma (pLELC) is a rare form of non-small cell lung cancer. As immunotherapy (IO) becomes an important treatment for advanced pLELC, identifying reliable prognostic markers is crucial for guiding clinical decisions and resource allocation.
methodsThis multicentre retrospective cohort study included 26 patients with advanced or metastatic pLELC who received palliative IO at two tertiary hospitals in Hong Kong from 2010 to 2023. Clinical and haematological data, particularly eosinophil peak timing, eosinophil-to-neutrophil ratio (ENR), and neutrophil-to-lymphocyte ratio (NLR), were obtained at each treatment cycle. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan-Meier analysis. Cox regression models, complemented by landmark and sensitivity analyses, were used to determine independent prognostic factors.
resultsEarly eosinophil peak (≤5 weeks after starting IO) was significantly linked to shorter PFS (HR 7.0, p = 0.007), while ENR <0.054 independently predicted poorer PFS (HR 2.9, p = 0.04). Neither ENR nor NLR showed significant associations with OS in multivariate analysis. Delayed eosinophil peaks were associated with more favourable PFS, supporting the prognostic value of eosinophil kinetics. Sensitivity analyses confirmed these findings were robust across patient subgroups.
conclusionsEosinophil peak timing is a practical, independent biomarker for identifying pLELC patients less likely to benefit from IO and may enhance patient prognostication and management. Further prospective studies in larger, multi-centre cohorts are needed to validate the clinical use of eosinophil dynamics in IO monitoring for pLELC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.